Physicians' Academy for Cardiovascular Education

A Randomized Phase 3 Trial Evaluating Alirocumab Every Four Weeks Dosing as Add-on to Statin or as Monotherapy: ODYSSEY CHOICE I

Slides (presentation) - June 19, 2015

Presentation prepared and held by Dr. Eli Roth (Cincinatti, Ohio, USA) in Clinical Breakthroughs session: Modifying LDL cholesterol to prevent CV events, Tuesday, May 26, 2015 during ISA2015 (Amsterdam, The Netherlands).

To view slides, click on images

Roth_CHOICE_I_ISA2015_Oral__R727_CL_1308__23May2015_FINAL.pdf (0,7MB)Roth_CHOICE_I_ISA2015_Oral__R727_CL_1308__23May2015_FINAL.pdf (0,7MB)

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.

Share this page with your colleagues and friends: